OncoZenge Future Growth
Future criteria checks 0/6
OncoZenge is forecast to grow earnings at 99.7% per annum. EPS is expected to grow by 99.9% per annum.
Key information
99.7%
Earnings growth rate
Pharmaceuticals earnings growth | 48.1% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 19 Feb 2024 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
OM:ONCOZ - Analysts future estimates and past financials data (SEK Millions)Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|
12/31/2023 | 0 | -16 | -17 | -17 | N/A |
9/30/2023 | N/A | -17 | -17 | -17 | N/A |
6/30/2023 | N/A | -16 | -14 | -14 | N/A |
3/31/2023 | N/A | -15 | -17 | -17 | N/A |
12/31/2022 | N/A | -47 | -22 | -22 | N/A |
9/30/2022 | N/A | -43 | -23 | -20 | N/A |
6/30/2022 | N/A | -41 | -22 | -19 | N/A |
3/31/2022 | N/A | -39 | -20 | -15 | N/A |
12/31/2021 | N/A | -4 | -10 | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ONCOZ is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ONCOZ is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ONCOZ is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if ONCOZ's revenue is forecast to grow faster than the Swedish market.
High Growth Revenue: Insufficient data to determine if ONCOZ's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ONCOZ's Return on Equity is forecast to be high in 3 years time
Discover growth companies